Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, July 26, 2022
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
[ Tue, Jul 26th 2022
] - WOPRAI
Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $30 on, Jul 26th, 2022
Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $27 to $30 on, Jul 26th, 2022.
Mani has made no other calls on BBIO in the last 4 months.
There is 1 other peer that has a rating on BBIO. Out of the 1 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mani
- Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $19 on, Tuesday, May 24th, 2022
